Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.51 |
| ▸ | RELA | Q04206 | 4/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998586 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKNR1H2 | |
| SCHEMBL31454797 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKNR1H2 | |
| SCHEMBL31454839 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKNR1H2 | |
| SCHEMBL3906310 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKNR1H2 | |
| SCHEMBL13628664 | 0.88 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL6058662 | 0.86 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL5545237 | 0.86 | NFKB1 (0.50) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL14511588 | 0.86 | NFKB1 (0.50) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL6058659 | 0.86 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL6058660 | 0.86 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0628044-B1 | THERAPEUTIC NUCLEOSIDES | WELLCOME FOUND (GB) | 2003-07-23 | — | — | EP | claimed |
| EP-1982985-A2 | Method for manufacturing a purine derivative | Lonza AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-7338945-B2 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino-2-cyclopentenyl-1-methanol | LONZA AG (CH) | 2008-03-04 | — | — | US | disclosed |
| US-20070123545-A1 | PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL | LONZA LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20060211862-A1 | PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL | LONZA INC. (US) | 2006-09-21 | — | — | US | disclosed |
| US-7071175-B1 | Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1418170-B1 | Process for the preparation of optically active amino alcohols by optical resolution | LONZA AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-1657243-A1 | Procedure for the production of amino alcohols | Lonza AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| EP-1508565-A1 | Process for the preparation of optically active aminoalcohols | Lonza AG (CH) | 2005-02-23 | — | — | EP | disclosed |
| EP-1502914-A1 | Process for the preparation of 1-amino-4-(hydroxymethyl)-2-cyclopentene derivatives | Lonza AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-6448402-B2 | REDUCTION OF 2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE USING METAL HYRIDE | LONZA AG (CH) | 2002-09-10 | — | — | US | disclosed |
| EP-1180098-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| US-20020010360-A1 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4-((2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1- methanol | LONZA AG (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6262295-B1 | REACTING CYCLOPENTENE-4-CARBOXYLIC ACID WITH AN ACYL HALIDE | LONZA A.G. (CH) | 2001-07-17 | — | — | US | disclosed |
| US-6252112-B1 | MIBCROBIAL HYDROLYSIS OF THE TITLE COMPOUND DERIVATIVE USING ENZYME HAVING N-ACETYLAMINO-ALCOHOL HYDROLASE OR PENICILLIN G ACYLASE ACTIVITY WITH SUBSEQUENT ACYLATION | LONZA A.G., (CH) | 2001-06-26 | — | — | US | disclosed |
| US-6156893-A | Process for the preparation of (1S,4R)- or (1R,4S)- 4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol | LONZA A.G. (CH) | 2000-12-05 | — | — | US | disclosed |
| WO-2000066557-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
| US-6137007-A | CHEMICAL INTERMEDIATES FOR NUCLEOSIDE, 4-2-(AMINO-6-CHLORO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL, WHICH IS AN INTERMEDIATE FOR 6-(CYCLOPROPYLAMINO)-DERIVATIVE | LONZA AG (CH) | 2000-10-24 | — | — | US | disclosed |
| EP-0926131-A2 | Process for the preparation of aminoalcohol derivatives and their further transformation zu (1R,4S)-4-((2-amino-6-chlor-5-formamido-4-pyrimidinyl)-amino)-2-cyclopenten-1-methanol | LONZA A.G. (CH) | 1999-06-30 | — | — | EP | disclosed |
| EP-0878548-A2 | Multistep process for the preparation of (1S,4R)- and/or (1R,4S)-4-(2-Amino-6-Chlor-9-H-purin-9-yl)-2-cyclopentene-1-methanol | LONZA AG (CH) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123545-A1 | PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL | GART, AASDHPPT, TYMS | NFKB1 3059/4885NFKB2 3584/4885RELA 3941/4885 |
| US-20020010360-A1 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4-((2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1- methanol | AASDHPPT, ALDH7A1, AADAT | NFKB1 3250/4885NFKB2 3400/4885RELA 3809/4885 |
| US-20060211862-A1 | PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL | GART, AASDHPPT, TYMS | NFKB1 3059/4885NFKB2 3584/4885RELA 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.